BUSCADOR RECOLECTA

We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost., Peer reviewed

To investigate the safety and immunogenicity of a modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B), a phase-I, doubled-blind placebo-controlled trial was performed., Peer reviewed

Attenuated poxvirus vectors expressing human immunodeficiency virus type 1 (HIV-1) antigens are considered promising HIV/AIDS vaccine candidates. Here, we describe the nature of T cell immune responses induced in healthy volunteers participating in a phase I clinical trial in Spain after intramuscular administration of three doses of the recombinant MVA-B-expressing monomeric gp120 and the fused Gag-Pol-Nef (GPN) polyprotein of clade B. The majority (92.3%) of the volunteers immunized had a positive specific T cell response at any time postvaccination as detected by gamma interferon (IFN-γ) intracellular cytokine staining (ICS) assay. The CD4(+) T cell responses were predominantly Env directed, whereas the CD8(+) T cell responses were similarly distributed against Env, Gag, and GPN. The proportion of responders after two doses of MVA-B was similar to that obtained after the third dose of MVA-B vaccination, and the responses were sustained (84.6% at week 48). Vaccine-induced CD8(+) T cells to HIV-1 antigens after 1 year were polyfunctional and distributed mainly within the effector memory (TEM) and terminally differentiated effector memory (TEMRA) T cell populations. Antivector T cell responses were mostly induced by CD8(+) T cells, highly polyfunctional, and of TEMRA phenotype. These findings demonstrate that the poxvirus MVA-B vaccine candidate given alone is highly immunogenic, inducing broad, polyfunctional, and long-lasting CD4 and CD8 T cell responses to HIV-1 antigens, with preference for TEM. Thus, on the basis of the immune profile of MVA-B in humans, this immunogen can be considered a promising HIV/AIDS vaccine candidate., Peer reviewed

Audiovisual sobre el grupo artístico 4 Elementes, autores de Postlibros, Peer reviewed

Vídeo conmemorativo, con el personal y la Dirección del IPNA-CSIC, sobre el Día de la Mujer y la Niña en la Ciencia, Peer reviewed

En este primer episodio, Santiago de Pablo y Virginia López de Maturana hablan sobre símbolos vascos. Descubriremos cuáles son los más importantes, su historia y la importancia que tienen para nuestra cultura. Además, conoceremos el origen del lauburu con Isabel Mellén y los fondos que atesora la Fundación Sancho el Sabio sobre el rock radical vasco con Ander Gondra. Gracias a Jabi Soto nos adentraremos en el fascinante mundo de los orígenes de la fotografía. ¡Descubre estos temas y mucho más en este primer episodio de El Podcast de Sancho el Sabio!

Forma part del fons personal de Bernard Lesfargues, Extraits de: Cap de l'aiga, Còr prendre, Ni cort ni costièr, Les amours des oursins, Finie la fête, La plus close nuit.

7 programes especials del programa "Fora d'hores" de Ràdio 4 produït pel "Laboratori de Produccions Sonores de Ficció i Entreteniment" de la Llicenciatura de Comunicació Audiovisual de la UAB dedicats a "Les mil i una nits", Emèsos entre maig i juny de 2010, Duració: 005958, 005959, 005959, 010000, 010002, 010000, 005959

Orofacial cleft is considered one of the commonest birth defects worldwide with a frequency of 1 per 500 live births. The Presurgical Nasoalveolar Molding (NAM) aims primarily to diminish the severity of the initial cleft condition. The primary objective of this study is to assess the perception, attitude, and opinions of parents and guardians of cleft palate patients, as well as their experience with pre-surgical orthopedics (NAM). 43 parents of children diagnosed of cleft lip/palate undergoing NAM treatment completed a questionnaire, and the responses are analyzed in this report. Most of respondents (79.1%) were mothers. Their ages fell predominantly within the range of 35-45 years (62.8%) or slightly younger (30.2% in the 25-35 age range). Only 23.3% were aware of the NAM treatment. The mother (39.5%) or both adults (55.8%) were responsible for managing the NAM. The baby's adaptation to NAM was favorable (average 3.4 ± 1.5; median 4.0)

Muestra de trabajo para la investigación titulada: "Educomunicación sexual en medios españoles".